Sign in
CompletedPhase 4

Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas

Key facts

Who runs it
Fayoum University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
66 people enrolled
Started
10 Aug 2025
Ended
13 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • loteprednol etabonate 1% arm 1
  • prednisolone acete 1%
Record updated
27 March 2026

Who can take part

Age
4 years to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Any patient presenting with an active anterior chamber granuloma
  • Patients must be treatment-naïve, having received no previous medical treatment for the current condition
  • Willingness of the parent or legal guardian to provide written informed consent

Who cannot take part

  • History of recurrent uveitis
  • Active corneal infection or corneal ulcer
  • Active inflammation clearly attributed to trauma, lens-induced causes, or underlying rheumatologic disease
  • Pre-existing glaucoma or a baseline intraocular pressure greater than 21 mmHg
  • Presence of a cataract
  • Evidence of active posterior uveitis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to compare the efficacy and safety of two different topical corticosteroids in 66 pediatric patients with active anterior chamber granuloma.

Read full original descriptionShow less

The main questions it aims to answer are:

* Does Loteprednol Etabonate 1% provide equivalent inflammation control and granuloma resolution compared to Prednisolone Acetate 1% over a 3-month period? * Does Loteprednol Etabonate 1% result in a lower frequency of steroid-related intraocular pressure (IOP) elevations than Prednisolone Acetate 1%? Researchers compared a group receiving Loteprednol Etabonate 1% four times daily to a group receiving Prednisolone Acetate 1% six times daily to see if Loteprednol could maintain comparable therapeutic effectiveness while offering a safer intraocular pressure profile.

Participants will Be randomized to receive either Loteprednol Etabonate 1% or Prednisolone Acetate 1% eye drops.

Follow a specific dosing schedule (4 times/day for Loteprednol or 6 times/day for Prednisolone).

Undergo a clinician-guided medication tapering schedule based on clinical response.

Attend follow-up assessments at day 1, 2 weeks, 1 month, and 3 months for eye examinations and pressure monitoring.

Be referred for surgical management if they do not demonstrate adequate clinical improvement after 4 weeks of therapy.

The 2 groups in the trial

  • loteprednol etabonate 1% groupTreatment being tested

    Participants in this group received loteprednol etabonate 1% eye drops administered four times daily. The treatment was followed by a clinician-guided tapering schedule based on the clinical improvement of anterior chamber activity and the reduction or clearance of the lesion as observed on slit-lamp examination.

    Treatment: loteprednol etabonate 1% arm 1

  • prednisolone acetate 1% groupExisting treatment, for comparison

    Participants in this group received prednisolone acetate 1% eye drops administered six times daily. As this medication is a suspension, patients were instructed to shake the bottle before each instillation. Similar to the first group, doses were tapered by the treating clinician according to the patient's clinical response and reduction in SUN anterior chamber grading.

    Treatment: prednisolone acete 1%

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas: A Randomized Study
Record updated
27 March 2026